Streptococcus Pneumoniae Infection Clinical Trial
Official title:
A Randomized Controlled Trial to Compare a 1-dose vs. 2-dose Priming Schedule of 13-valent Pneumococcal Conjugate Vaccine in Canadian Infants; a Canadian Immunization Research Network (CIRN) Study
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3 doses at 2, 4 and 12 months of age. This study aims to find out if it is possible to achieve the same protection using just 2 doses, at 2 and 12 months.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05060146 -
Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.
|
N/A | |
Not yet recruiting |
NCT05017519 -
Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus
|
||
Recruiting |
NCT05759520 -
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
|
Phase 3 | |
Completed |
NCT05361499 -
A Controlled Human Pneumococcal Infection Model (PIM) Study
|
N/A | |
Active, not recruiting |
NCT03489018 -
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
|
Phase 4 | |
Completed |
NCT03696303 -
Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala
|
||
Active, not recruiting |
NCT03102840 -
Understanding Pneumococcal Carriage and Disease 2017-2020
|
||
Completed |
NCT00189020 -
Effect of Two Versus Three Pneumococcal Conjugate Vaccinations
|
Phase 3 | |
Completed |
NCT02037984 -
Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04944719 -
Pneumococcal Nasopharyngeal Colonization as Predictor of Community-Acquired Pneumonia (CAP) in Adults With Chronic Diseases.
|